SOURCE: TomoTherapy

TomoTherapy

May 18, 2010 16:00 ET

TomoTherapy EMEA User Education Symposium Brings Together Users Throughout Europe and the Middle East

Educational, User-Driven Conference Features Results From 25 Scientific Presentations and 30 Posters on Efficacy of TomoTherapy® System to Treat Wide Range of Cancers

MADISON, WI--(Marketwire - May 18, 2010) -  TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, recently hosted the second of three regional 2010 educational symposia, this one for users of the TomoTherapy® treatment system in Europe and the Middle East. More than 25 abstracts and 30 poster presentations detailing the clinical use of TomoTherapy technology to treat a wide range of cancers were featured May 6-8 during the 2010 EMEA User Symposium in Marbella, Spain.

"TomoTherapy users are embracing our educational symposia, as evidenced by their growing popularity and the overwhelming response to our call for clinical abstracts," said Jef Van Dam, general manager, EMEA for TomoTherapy. "This year's event -- our fifth for this region -- attracted representatives from every TomoTherapy treatment facility in Europe and the Middle East and underscores the vast importance of providing a setting in which our customers can discuss best practices and learn first-hand about new clinical uses of the technology."

The 2010 EMEA User Symposium opened with a presentation from Dr. Carlos A. Perez, an internationally renowned specialist in radiation oncology who serves as professor emeritus at Washington University. Dr. Perez addressed recent advances in the field and the future of radiation oncology.

Other highlights of the symposium included interactive workshops for treatment planning. These workshops were divided into three sessions, with one focusing on the fundamentals of TomoTherapy treatment planning, a second featuring complex cases for more experienced users, and a third session for attendees interested in learning more about planning for stereotactic radiosurgery (SRS), stereotactic radiation therapy (SRT) and stereotactic body radiation therapy (SBRT) cases with the TomoTherapy system.

A total of 75 abstracts were submitted for the symposium, nearly double the number of abstracts submitted for the 2009 meeting. This year the program was expanded to include 25 abstracts and 30 posters, to showcase application of the TomoTherapy system for treatment of lung, prostate, head and neck, brain, colorectal and gynecological cancers, among other diseases. Highlights of the scientific presentations included:

  • Lung cancer -- In a study at Scientific Institute San Raffaele in Milan, Italy, researchers tested the feasibility of dose escalation with TomoTherapy technology for treating patients with malignant pleural mesothelioma. Some patients in the study received a simultaneous integrated boost dose to regions seen on PET scans to have a higher tumor cell concentration. Results showed statistically significant improvements in survival and better local control for those patients given a boost.
  • Gynecological cancers -- An abstract from RISO Deventer in the Netherlands looked at radiotherapy treatment for post-operative endometrial cancer patients, and the ability of the TomoTherapy system's helical delivery capability to help reduce dosages to surrounding organs. The result of this study showed that the average irradiated volume of the small bowel, bladder and rectum was reduced for the high dose levels (≥ 35 Gy) compared to conventional conformal therapy. Two posters from Charité Berlin Campus Virchow Klinikum in Berlin, Germany, also focused on treatment of cervical cancer.
  • Colorectal cancer -- In a study at Universitair Ziekenhuis Brussel in Brussels, Belgium, researchers explored the efficacy and toxicity of helical TomoTherapy in the preoperative treatment of rectal cancer. Reviewing results of 106 patients, it was shown that TomoTherapy technology helps reduce acute toxicity, and that a simultaneous integrated radiation boost increases the metabolic response without excessive toxicity.
  • Total Marrow Irradiation (TMI) -- In this study done at the Istituto Nazionale per la Ricera sul Cancro in Genova, Italy, researchers showed how helical TomoTherapy delivery has enabled them to obtain a conformal and uniform dose distribution throughout the entire skeleton in patients with blood cancer, prior to bone marrow transplant. A poster presentation from Radiologische Universitätsklinik in Bonn, Germany, also focused on "semiconductor based in-vivo dosimetry for TMI using helical IMRT." TMI using TomoTherapy technology was pioneered at City of Hope in the United States, and is currently being used at several TomoTherapy treatment centers globally.
  • Prostate cancer -- A series of four clinical papers from Scientific Institute San Raffaele in Milan, Italy, examined the use of TomoTherapy technology in treating prostate cancer. These studies focused on the efficacy of hypofractionation, as well as the ability to limit toxicity and safely escalate dosage.
  • Pediatric cancers -- Researchers from Grupo IMO, Hospital La Milagrosa de Madrid in Madrid, Spain, examined the use of the TomoTherapy system for treating pediatric patients in an effort to preserve healthy organs. The clinical study concluded that TomoTherapy technology allowed manageable levels of toxicity in pediatrics, but long term follow-up is required to determine its actual benefits for these patients.

The first User Education Symposium, for the Americas region, was held April 15-17, in San Diego. The final event in this series is the Asian symposium, scheduled for October 2-3 in Incheon, Korea.

More than 130 TomoTherapy customers attended the 2010 EMEA User Education Symposium, including physicians, physicists and radiographers.

About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    608.824.2800
    Email Contact
    Media Contacts:
    Kevin O'Malley
    Director, Corporate Communications
    608.824.3384
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    510.832.6006
    Email Contact